Prostate-specific antigen-based screening for prostate cancer in the third millennium: Useful or hype?

Annals of Medicine

Volumn 41, Issue 7, 2009, Pages 480-489

  Lippi, Giuseppe ^a,c   Montagnana, Martina ^a   Guidi, Gian Cesare ^a   Plebani, Mario ^b  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^c UNIVERSITY OF VERONA   (Italy)

Author keywords

Prostate; Prostate cancer; Prostate specific antigen; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

BODY MASS; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER MORTALITY; CANCER SCREENING; CHEMICAL ANALYSIS; CONCENTRATION (PARAMETERS); COST EFFECTIVENESS ANALYSIS; DEMOGRAPHY; ETHNICITY; FAMILY HISTORY; GENOTYPE; GROWTH RATE; HUMAN; MANAGED CARE; MASS SCREENING; MEDICAL DECISION MAKING; PATIENT IDENTIFICATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; REVIEW;

AGE FACTORS; AGED; AGED, 80 AND OVER; EARLY DETECTION OF CANCER; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 70349952103     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.1080/07853890903156468     Document Type: Review

References (92)

1. Lim LS, Sherin K. ACPM Prevention Practice Committee. Screening for prostate cancer in U.S. men ACPM position statement on preventive practice. Am J Prev Med. 2008;34: 164-170
2. Sutcliffe P, Hummel S, Simpson E, Young T, Rees A, Wilkinson A, et al. Use of classical and novel biomarkers as prognostic risk factors for localised prostate cancer: a systematic review. Health Technol Assess. 2009;13:iii, xi-xiii, 1-219.
3. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol. 2004;16:481-488
4. Baade PD, Youlden DR, Krnjacki LJ. International epidemiology of prostate cancer: geographical distribution and secular trends. Mol Nutr Food Res. 2009;53:171-184
5. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-9.
6. Gann PH. Risk factors for prostate cancer. Rev Urol. 2002;4(Suppl 5):S3-10.
7. Powell IJ. Epidemiology and pathophysiology of prostate cancer in African-American men. J Urol. 2007;177:444-449
8. Jones BA, Liu WL, Araujo AB, Kasl SV, Silvera SN, Soler-Vila H, et al. Explaining the race difference in prostate cancer stage at diagnosis. Cancer Epidemiol Biomarkers Prev. 2008;17:2825-2834
9. Freedland SJ, Isaacs WB. Explaining racial differences in prostate cancer in the United States: sociology or biology? Prostate. 2005;62:243-252
10. Damber JE, Aus G. Prostate cancer. Lancet. 2008;371: 1710-1721
11. Pienta KJ, Esper PS. Risk factors for prostate cancer. Ann Intern Med. 1993;118:793-803.
12. Edwards CN, Steinthosson E, Nicholson D. An autopsy study of latent prostatic cancer. Cancer. 1953;6:531-554
13. Halpert B, Sheehan E, Schmalhorst W, Scott R. Carcinoma of the prostate: A survey of 5000 autopsies. Cancer. 1963;16:737-2.
14. Cerhan JR, Parker AS, Putnam SD, Chiu BCH, Lynch CF, Cohen MB, et al. Family history and prostate cancer risk in a population-based cohort of Iowa men. Cancer Epidemiol Biomarkers Prev. 1999;8:53-60.
15. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, et al. Environmental and heritable factors in the causation of cancer*analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000;343: 78-85.
16. Page WF, Braun MM, Partin AW, Caporaso N, Walsh P. Heredity and prostate cancer: a study of World War II veteran twins. Prostate. 1997;33:240-245
17. Gibbs M, Stanford JL, Jarvik GP, Janer M, Badzioch M, Peters MA, et al. A genomic scan of families with prostate cancer identifies multiple regions of interest. Am J Hum Genet. 2000;67:100-109
18. Berthon P, Valeri A, Cohen-Akenine A, Drelon E, Paiss T, Wohr G, et al. Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43. Am J Hum Genet. 1998;62:1416-1424
19. Gibbs M, Stanford JL, McIndoe RA, Jarvik GP, Kolb S, Goode EL, et al. Evidence for a rare prostate cancer susceptibility locus at chromosome 1p36. Am J Hum Genet. 1999;64:776-787
20. Xu J, Meyers D, Freije D, Isaacs S, Wiley K, Nusskern D, et al. Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet. 1998;20:175-179
21. Berry R, Schroeder JJ, French AJ, McDonnell SK, Peterson BJ, Cunningham JM, et al. Evidence for a prostate cancer-susceptibility locus on chromosome 20. Am J Hum Genet. 2000;67:82-91.
22. Lange EM, Gillanders EM, Davis CC, Brown WM, Campbell JK, Jones M, et al. Genome-wide scan for prostate cancer susceptibility genes using families from the University of Michigan prostate cancer genetics project finds evidence for linkage on chromosome 17 near BRCA1. Prostate. 2003;57:326-334
23. Stanford JL, Fitzgerald LM, McDonnell SK, Carlson EE, McIntosh LM, Deutsch K, et al. Dense genome-wide SNP linkage scan in 301 hereditary prostate cancer families identifies multiple regions with suggestive evidence for linkage. Hum Mol Genet. 2009;18:1839-8.
24. Hsing AW. Hormones and prostate cancer: Where do we go from here? J Natl Cancer Inst. 1996;88:1093-1095
25. Putnam SD, Cerhan JR, Parker AS, Bianchi GD, Wallace RB, Cantor KP, et al. Lifestyle and anthropometric risk factors for prostate cancer in a cohort of Iowa men. Ann Epidemiol. 2000;10:361-369
26. Rao AR, Motiwala HG, Karim OM. The discovery of prostate-specific antigen. BJU Int. 2008;101:5-10.
27. Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. Invest Urol. 1979;17:159-163
28. Papsidero LD, Wang MC, Valenzuela LA, Murphy GP, Chu TM. A prostate antigen in sera of prostatic cancer patients. Cancer Res. 1980;40:2428-2432
29. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317: 909-916
30. Belanger A, van Halbeek H, Graves HC, Grandbois K, Stamey TA, Huang L, et al. Molecular mass and carbohydrate structure of prostate specific antigen: studies for establishment of an international PSA standard. Prostate. 1995;27:187-197
31. Lundwall A, Lilja H. Molecular cloning of human prostate-specific antigen cDNA. FEBS Lett. 1987;214:317-322
32. Kumar A, Mikolajczyk SD, Goel AS, Millar LS, Saedi MS. Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2. Cancer Res. 1997;57:3111-.
33. Schieferstein G. Prostate-specific antigen (PSA) in human seminal plasma. Arch Androl. 1999;42:193-197
34. Lilja H, Christensson A, Dahlen U, Matikainen MT, Nilsson O, Pettersson K, et al. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymo-trypsin. Clin Chem. 1991;37:1618-1625
35. Malm J, Lilja H. Biochemistry of prostate specific antigen, PSA. Scand J Clin Lab Invest Suppl. 1995;221:15-22.
36. Liang SL. Application of prostate-specific antigen in prostate cancer. MLO Med Lab Obs. 2008;40:54, 56-57
37. Stenman U, Finne P, Zhang W, Leinonen J. Prostate-specific antigen and other prostate cancer markers. Urology. 2000;56:893-898
38. Basso D, Fogar P, Piva MG, Navaglia F, Mazza S, Prayer-Galetti T, et al. Total PSA, free PSA/total PSA ratio, and molecular PSA detection in prostate cancer: which is clinically effective and when? Urology. 2000;55:710-715
39. Diamandis EP. Prostate-specific antigen: a cancer fighter and a valuable messenger? Clin Chem. 2000;46:896-900.
40. Loeb S, Catalona WJ. Prostate-specific antigen in clinical practice. Cancer Lett. 2007;249:30-39
41. Thompson IM, Ankerst DP. Prostate-specific antigen in the early detection of prostate cancer. CMAJ. 2007;176:1853-1858
42. Thompson IM Pauler DK Goodman PJ Tangen CM Lucia MS Parnes HL et ali Prevalence of prostate cancer among men with a prostate-specific antigen level >or =4.0 ng per milliliter. N Engl J Med. 2004;350:2239-6
43. Loeb S, Roehl KA, Antenor JA, Catalona WJ, Suarez BK, Nadler RB. Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology. 2006;67:316-320
44. Labrie F, Dupont A, Suburu R, Cusan L, Tremblay M, Gomez JL, et al. Serum prostate specific antigen as pre-screening test for prostate cancer. J Urol. 1992;147:846-851
45. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA. 1997;277: 1452-1455
46. Roobol MJ, Kirkels WJ, Schroder FH. Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, The Netherlands). BJU Int. 2003;92(Suppl 2): 48-54.
47. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al.; ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320-1328
48. Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, Lucia MS, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2006;98:529-534 (Pubitemid 43898816)
49. Parekh DJ, Ankerst DP, Higgins BA, Hernandez J, Canby-Hagino E, Brand T, et al. External validation of the Prostate Cancer Prevention Trial risk calculator. Urology. 2006;68:1152-1155
50. Prostate-specific antigen (PSA) best practice policy. American Urological Association (AUA). Oncology (Williston Park). 2000;14:267-272
51. Smith RA, Cokkinides V, Eyre HJ. American Cancer Society guidelines for the early detection of cancer, 2006. CA Cancer J Clin. 2006;56:11-25.
52. Kawachi MH, Bahnson RR, Barry M, Carroll PR, Carter HB, Catalona WJ, et al.; National Comprehensive Cancer Network. Prostate cancer early detection. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2007;5: 714-736
53. Kerfoot BP, Holmberg EF, Lawler EV, Krupat E, Conlin PR. Practitioner-level determinants of inappropriate prostate-specific antigen screening. Arch Intern Med. 2007;167: 1367-1372
54. Lippi G, Montagnana M, Guidi GC. Improving appropriateness of prostate-specific antigen screening. Arch Intern Med. 2007;167:2529-2530
55. Panteghini M, Pagani F, Bonora R. Pre-analytical and biological variability of prostatic acid phosphatase and prostate-specific antigen in serum from patients with prostatic pathology. Eur J Clin Chem Clin Biochem. 1992;30: 135-139
56. Wiklund F, Zheng SL, Sun J, Adami HO, Lilja H, Hsu FC, et al. Association of reported prostate cancer risk alleles with PSA levels among men without a diagnosis of prostate cancer. Prostate. 2009;69:419-427
57. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA. 1993;270:860.
58. Oesterling JE, Jacobsen SJ, Klee GG, Pettersson K, Piironen T, Abrahamsson PA, et al. Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J Urol. 1995;154:1090-1095
59. Cooney KA, Strawderman MS, Wojno KJ, Doerr KM, Taylor A, Alcser KH, et al. Age-specific distribution of serum prostate-specific antigen in a community-based study of African-American men. Urology. 2001;57:91-96
60. Tewari A, Horninger W, Badani KK, Hasan M, Coon S, Crawford ED, et al. Racial differences in serum prostate-specific antigen (PSA) doubling time, histopathological variables and long-term PSA recurrence between African-American and white American men undergoing radical prostatectomy for clinically localized prostate cancer. BJU Int. 2005;96:29-33.
61. Lacher DA, Thompson TD, Hughes JP, Saraiya M. Total, free, and percent free prostate-specific antigen levels among U.S. men, 2001-2004. Adv Data. 2006;1-12.
62. Fowke JH, Signorello LB, Chang SS, Matthews CE, Buchowski MS, Cookson MS, et al. Effects of obesity and height on prostate-specific antigen (PSA) and percentage of free PSA levels among African-American and Caucasian men. Cancer. 2006;107:2361-2367
63. Fowke JH, Signorello LB, Underwood W 3rd, Ukoli FA, Blot WJ. Obesity and prostate cancer screening among African-American and Caucasian men. Prostate. 2006;66:1371-1380
64. Rundle A, Richards C, Neugut AI. Body composition, abdominal fat distribution, and prostate-specific antigen test results. Cancer Epidemiol Biomarkers Prev. 2009;18:331-336
65. Lippi G, Montagnana M, Guidi GC. Epidemiological association between C-reactive protein and prostate-specific antigen. Cancer. 2009;115:1132.
66. Stamey TA, Chen Z, Prestigiacomo AF Reference material for PSA: the IFCC standardization study. International Federation of Clinical Chemistry. Clin Biochem. 1998;31: 475-481
67. Rafferty B, Rigsby P, Rose M, Stamey T, Gaines Das R. Reference reagents for prostate-specific antigen (PSA): establishment of the first international standards for free PSA and PSA (90:10). Clin Chem. 2000;46:1310-1317
68. Loeb S, Chan DW, Sokoll L, Kan D, Maggiore J, Mikolajczyk SD, et al. Prostate specific antigen assay standardization bias could affect clinical decision making. J Urol. 2008;180: 1959-1962
69. Stephan C, Kahrs AM, Klotzek S, Reiche J, Müller C, Lein M, et al. Toward metrological traceability in the determination of prostate-specific antigen (PSA): calibrating Beckman Coulter Hybritech Access PSA assays to WHO standards compared with the traditional Hybritech standards. Clin Chem Lab Med. 2008;46:623-629
70. Jansen FH, Roobol M, Bangma CH, van Schaik RH. Clinical impact of new prostate-specific antigen WHO standardization on biopsy rates and cancer detection. Clin Chem. 2008;54:1999-2006.
71. Stephan C, Klaas M, Müller C, Schnorr D, Loening SA, Jung K. Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update. Clin Chem. 2006;52:59-64.
72. Kort SA, Martens F, Vanpoucke H, van Duijnhoven HL, Blankenstein MA. Comparison of 6 automated assays for total and free prostate-specific antigen with special reference to their reactivity toward the WHO 96/670 reference preparation. Clin Chem. 2006;52:1568-1574
73. Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst. 2009;101:374-383
74. Labrie F, Candas B, Cusan L, Gomez JL, Belanger A, Brousseau G, et al. Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial. Prostate. 2004;59:311-318
75. Ilic D, O'Connor D, Green S, Wilt T. Screening for prostate cancer. Cochrane Database Syst Rev. 2006;3:CD004720.
76. Sandblom G, Varenhorst E, Lofman O, Rosell J, Carlsson P. Clinical consequences of screening for prostate cancer: 15 years follow-up of a randomised controlled trial in Sweden. Eur Urol. 2004;46:717-723 (Pubitemid 39488400)
77. Andriole GL, Grubb RL 3rd, Buys SS, Chia D, Church TR, Fouad MN, et al.; PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360:1310-1319
78. de Koning HJ, Liem MK, Baan CA, Boer R, Schroder FH, Alexander FE. Prostate cancer mortality reduction by screening: power and time frame with complete enrollment in the European Randomised Screening for Prostate Cancer (ERSPC) trial. Int J Cancer. 2002;98:268-273
79. Zambon CF, Basso D, Prayer-Galetti T, Navaglia F, Fasolo M, Fogar P, et al. Quantitative PSA mRNA determination in blood: a biochemical tool for scoring localized prostate cancer. Clin Biochem. 2006;39:333-338
80. Gelmini S, Tricarico C, Petrone L, Forti G, Amorosi A, Dedola GL, et al. Real-time RT-PCR for the measurement of prostate-specific antigen mRNA expression in benign hyperplasia and adenocarcinoma of prostate. Clin Chem Lab Med. 2003;41:261-265
81. Downes MR, Byrne JC, Pennington SR, Dunn MJ, Fitzpa-trick JM, Watson RW Urinary markers for prostate cancer. BJU Int. 2007;99:263-268
82. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009;457:910-914
83. Shariat SF, Scardino PT, Lilja H. Screening for prostate cancer: an update. Can J Urol. 2008;15:4363-4374
84. Vanaja DK, Ehrich M, Van den Boom D, Cheville JC, Karnes RJ, Tindall DJ, et al. Hypermethylation of genes for diagnosis and risk stratification of prostate cancer. Cancer Invest. 2009;27:549-560
85. Sardana G, Dowell B, Diamandis EP Emerging biomarkers for the diagnosis and prognosis of prostate cancer. Clin Chem. 2008;54:1951-1960
86. Stavropoulou P, Gregorakis AK, Plebani M, Scorilas A. Expression analysis and prognostic significance of human kallikrein 11 in prostate cancer. Clin Chim Acta. 2005;357: 190-195
87. Scorilas A, Plebani M, Mazza S, Basso D, Soosaipillai AR, Katsaros N, et al. Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and%free PSA. Prostate. 2003;54:220-229
88. Petricoin EF 3rd, Ornstein DK, Paweletz CP, Ardekani A, Hackett PS, Hitt BA, et al. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst. 2002;94: 1576-1578 (Pubitemid 35277282)
89. Abate-Shen C, Shen MM. Diagnostics: The prostate-cancer metabolome. Nature. 2009;457:799-800.
90. Nam RK, Zhang WW, Trachtenberg J, Seth A, Klotz LH, Stanimirovic A, et al. Utility of incorporating genetic variants for the early detection of prostate cancer. Clin Cancer Res. 2009;15:1787-1793
91. Litwin MS, Saigal CS, Lubeck DP, Li YP, Henning JM, Carroll PR. Health-related quality of life in men with metastatic prostate cancer: the misleading effect of lead-time bias. BJU Int. 2003;91:9-13.
92. Saigal CS, Litwin MS. The economic costs of early stage prostate cancer. Pharmacoeconomics. 2002;20:869-878